Eli Lilly and Company announced on October 6, 2025, a significant investment of over $1 billion into new contract manufacturing in India. The investment includes the establishment of a new facility in Hyderabad that will provide advanced technical capabilities and oversee its contract manufacturing network across the country. This move is intended to expand Lilly's global manufacturing and supply capacity for its portfolio of medicines, particularly for new treatments in diabetes, obesity, Alzheimer's disease, cancer, and autoimmune conditions. The announcement was made after a meeting between company leadership and government officials in Telangana. This investment is seen as a strategic move to leverage India's skilled workforce and growing pharmaceutical manufacturing capabilities. There was no specific market reaction analysis available for October 11, 2025.